{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:18:38Z","timestamp":1792095518393,"version":"4.4.0"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41581-023-00800-2","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T10:03:11Z","timestamp":1705917791000},"page":"233-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Metabolic alterations in hereditary and sporadic renal cell carcinoma"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-5533","authenticated-orcid":false,"given":"Nathan J.","family":"Coffey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Celeste","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bju.13185","volume":"117","author":"S Kalra","year":"2016","unstructured":"Kalra, S. et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 117, 761\u2013765 (2016).","journal-title":"BJU Int."},{"key":"800_CR3","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1158\/2159-8290.CD-21-0211","volume":"11","author":"R Riscal","year":"2021","unstructured":"Riscal, R. et al. Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma. Cancer Discov. 11, 3106\u20133125 (2021).","journal-title":"Cancer Discov."},{"key":"800_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"800_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cell.2018.03.055","volume":"173","author":"C Jang","year":"2018","unstructured":"Jang, C., Chen, L. & Rabinowitz, J. D. Metabolomics and isotope tracing. Cell 173, 822\u2013837 (2018).","journal-title":"Cell"},{"key":"800_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739\u2013744 (2009).","journal-title":"Nature"},{"key":"800_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"800_CR8","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1016\/j.molcel.2022.07.007","volume":"82","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells. Mol. Cell 82, 3270\u20133283.e3279 (2022).","journal-title":"Mol. Cell"},{"key":"800_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.molcel.2020.12.012","volume":"81","author":"A Luengo","year":"2021","unstructured":"Luengo, A. et al. Increased demand for NAD(+) relative to ATP drives aerobic glycolysis. Mol. Cell 81, 691\u2013707.e696 (2021).","journal-title":"Mol. Cell"},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"ER Maher","year":"1990","unstructured":"Maher, E. R. et al. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77, 1151\u20131163 (1990).","journal-title":"Q. J. Med."},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/0008-5472.CAN-09-0146","volume":"69","author":"R Beroukhim","year":"2009","unstructured":"Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in Von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674\u20134681 (2009).","journal-title":"Cancer Res."},{"key":"800_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510\u20135514 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1093\/nar\/gkp1205","volume":"38","author":"A Ortiz-Barahona","year":"2010","unstructured":"Ortiz-Barahona, A., Villar, D., Pescador, N., Amigo, J. & del Peso, L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res. 38, 2332\u20132345 (2010).","journal-title":"Nucleic Acids Res."},{"key":"800_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846401","volume":"20","author":"JA Smythies","year":"2019","unstructured":"Smythies, J. A. et al. Inherent DNA-binding specificities of the HIF-1\u03b1 and HIF-2\u03b1 transcription factors in chromatin. EMBO Rep. 20, e46401 (2019).","journal-title":"EMBO Rep."},{"key":"800_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-022-00587-8","volume":"18","author":"CT Taylor","year":"2022","unstructured":"Taylor, C. T. & Scholz, C. C. The effect of HIF on metabolism and immunity. Nat. Rev. Nephrol. 18, 573\u2013587 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"800_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1101\/gad.12.2.149","volume":"12","author":"NV Iyer","year":"1998","unstructured":"Iyer, N. V. et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1\u03b1. Genes. Dev. 12, 149\u2013162 (1998).","journal-title":"Genes. Dev."},{"key":"800_CR18","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604\u20134613 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","volume":"93","author":"BD Kelly","year":"2003","unstructured":"Kelly, B. D. et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074\u20131081 (2003).","journal-title":"Circ. Res."},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584\u20133590 (2009).","journal-title":"J. Clin. Oncol."},{"key":"800_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"JW Kim","year":"2006","unstructured":"Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177\u2013185 (2006).","journal-title":"Cell Metab."},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"32529","DOI":"10.1074\/jbc.271.51.32529","volume":"271","author":"GL Semenza","year":"1996","unstructured":"Semenza, G. L. et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529\u201332537 (1996).","journal-title":"J. Biol. Chem."},{"key":"800_CR23","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1074\/jbc.M511397200","volume":"281","author":"MS Ullah","year":"2006","unstructured":"Ullah, M. S., Davies, A. J. & Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 281, 9030\u20139037 (2006).","journal-title":"J. Biol. Chem."},{"key":"800_CR24","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","volume":"62","author":"R Xu","year":"2019","unstructured":"Xu, R. et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876\u20136893 (2019).","journal-title":"J. Med. Chem."},{"key":"800_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"800_CR26","doi-asserted-by":"publisher","first-page":"9691","DOI":"10.1021\/acs.jmedchem.8b01196","volume":"61","author":"PM Wehn","year":"2018","unstructured":"Wehn, P. M. et al. Design and activity of specific hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J. Med. Chem. 61, 9691\u20139721 (2018).","journal-title":"J. Med. Chem."},{"key":"800_CR27","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E. et al. Belzutifan for renal cell carcinoma in Von Hippel\u2013Lindau disease. N. Engl. J. Med. 385, 2036\u20132046 (2021).","journal-title":"N. Engl. J. Med."},{"key":"800_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"800_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120403119","volume":"119","author":"LA Stransky","year":"2022","unstructured":"Stransky, L. A. et al. Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc. Natl Acad. Sci. USA 119, e2120403119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793\u2013803 (2020).","journal-title":"Clin. Cancer Res."},{"key":"800_CR31","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1093\/hmg\/ddac066","volume":"31","author":"A Andreou","year":"2022","unstructured":"Andreou, A. et al. Elongin C (ELOC\/TCEB1)-associated von Hippel-Lindau disease. Hum. Mol. Genet. 31, 2728\u20132737 (2022).","journal-title":"Hum. Mol. Genet."},{"key":"800_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/modpathol.2015.6","volume":"28","author":"AA Hakimi","year":"2015","unstructured":"Hakimi, A. A. et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod. Pathol. 28, 845\u2013853 (2015).","journal-title":"Mod. Pathol."},{"key":"800_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860\u2013867 (2013).","journal-title":"Nat. Genet."},{"key":"800_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"800_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K.-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648\u2013657 (2002).","journal-title":"Nat. Cell Biol."},{"key":"800_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrm2672","volume":"10","author":"XM Ma","year":"2009","unstructured":"Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307\u2013318 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"800_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"key":"800_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68\u201373 (1997).","journal-title":"Nat. Genet."},{"key":"800_CR39","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","volume":"36","author":"ER Maher","year":"2018","unstructured":"Maher, E. R. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J. Urol. 36, 1891\u20131898 (2018).","journal-title":"World J. Urol."},{"key":"800_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"WM Linehan","year":"2016","unstructured":"Linehan, W. M. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135\u2013145 (2016).","journal-title":"N. Engl. J. Med."},{"key":"800_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143468","volume":"10","author":"X Yin","year":"2015","unstructured":"Yin, X. et al. Relationships between chromosome 7 gain, MET gene copy number increase and MET protein overexpression in Chinese papillary renal cell carcinoma patients. PLoS ONE\u00a010, e0143468 (2015).","journal-title":"PLoS ONE"},{"key":"800_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/34657","volume":"391","author":"C Boccaccio","year":"1998","unstructured":"Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285\u2013288 (1998).","journal-title":"Nature"},{"key":"800_CR43","first-page":"4600","volume":"13","author":"C Ponzetto","year":"1993","unstructured":"Ponzetto, C. et al. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor\/scatter factor receptor. Mol. Cell Biol. 13, 4600\u20134608 (1993).","journal-title":"Mol. Cell Biol."},{"key":"800_CR44","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.1016\/S0021-9258(18)98327-4","volume":"268","author":"A Graziani","year":"1993","unstructured":"Graziani, A., Gramaglia, D., dalla Zonca, P. & Comoglio, P. M. Hepatocyte growth factor\/scatter factor stimulates the Ras-guanine nucleotide exchanger. J. Biol. Chem. 268, 9165\u20139168 (1993).","journal-title":"J. Biol. Chem."},{"key":"800_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","volume":"31","author":"TK Choueiri","year":"2013","unstructured":"Choueiri, T. K. et al. Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181\u2013186 (2013).","journal-title":"J. Clin. Oncol."},{"key":"800_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-020-00148-7","volume":"5","author":"RH Kim","year":"2020","unstructured":"Kim, R. H. et al. Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome. NPJ Genom. Med. 5, 40 (2020).","journal-title":"NPJ Genom. Med."},{"key":"800_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/path.6009","volume":"258","author":"P Tibarewal","year":"2022","unstructured":"Tibarewal, P. et al. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development. J. Pathol. 258, 382\u2013394 (2022).","journal-title":"J. Pathol."},{"key":"800_CR48","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1158\/0008-5472.CAN-08-0922","volume":"68","author":"CH Squarize","year":"2008","unstructured":"Squarize, C. H., Castilho, R. M. & Gutkind, J. S. Chemoprevention and treatment of experimental Cowden\u2019s disease by mTOR inhibition with rapamycin. Cancer Res. 68, 7066\u20137072 (2008).","journal-title":"Cancer Res."},{"key":"800_CR49","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1634\/theoncologist.2019-0514","volume":"24","author":"T Komiya","year":"2019","unstructured":"Komiya, T. et al. A pilot study of sirolimus in subjects with Cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist 24, 1510\u2013e1265 (2019).","journal-title":"Oncologist"},{"key":"800_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-018-3610-z","volume":"82","author":"J Rodon","year":"2018","unstructured":"Rodon, J. et al. Phase 1\/1b dose escalation and expansion study of BEZ235, a dual PI3K\/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother. Pharmacol. 82, 285\u2013298 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"800_CR51","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","volume":"38","author":"P Yang","year":"2014","unstructured":"Yang, P. et al. Renal cell carcinoma in tuberous sclerosis complex. Am. J. Surg. Pathol. 38, 895\u2013909 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"800_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"800_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.6004\/jnccn.2017.7041","volume":"16","author":"P Maroto","year":"2018","unstructured":"Maroto, P. et al. Biallelic TSC2 mutations in a patient with chromophobe renal cell carcinoma showing extraordinary response to temsirolimus. J. Natl Compr. Canc Netw. 16, 352\u2013358 (2018).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"800_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","volume":"2","author":"ML Nickerson","year":"2002","unstructured":"Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub\u00e9 syndrome. Cancer Cell 2, 157\u2013164 (2002).","journal-title":"Cancer Cell"},{"key":"800_CR55","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/onc.2010.497","volume":"30","author":"RS Preston","year":"2011","unstructured":"Preston, R. S. et al. Absence of the Birt-Hogg-Dub\u00e9 gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 30, 1159\u20131173 (2011).","journal-title":"Oncogene"},{"key":"800_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.gene.2008.02.022","volume":"415","author":"H Hasumi","year":"2008","unstructured":"Hasumi, H. et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415, 60\u201367 (2008).","journal-title":"Gene"},{"key":"800_CR57","doi-asserted-by":"publisher","first-page":"15552","DOI":"10.1073\/pnas.0603781103","volume":"103","author":"M Baba","year":"2006","unstructured":"Baba, M. et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl Acad. Sci. USA 103, 15552\u201315557 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR58","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.aax0364","volume":"366","author":"RE Lawrence","year":"2019","unstructured":"Lawrence, R. E. et al. Structural mechanism of a Rag GTPase activation checkpoint by the lysosomal folliculin complex. Science 366, 971\u2013977 (2019).","journal-title":"Science"},{"key":"800_CR59","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cell.2019.10.036","volume":"179","author":"K Shen","year":"2019","unstructured":"Shen, K. et al. Cryo-EM structure of the human FLCN-FNIP2-Rag-ragulator complex. Cell 179, 1319\u20131329.e1318 (2019).","journal-title":"Cell"},{"key":"800_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003581","volume":"3","author":"J Chen","year":"2008","unstructured":"Chen, J. et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS ONE\u00a03, e3581 (2008).","journal-title":"PLoS ONE"},{"key":"800_CR61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-020-2444-0","volume":"585","author":"G Napolitano","year":"2020","unstructured":"Napolitano, G. et al. A substrate-specific mTORC1 pathway underlies Birt\u2013Hogg\u2013Dub\u00e9 syndrome. Nature 585, 597\u2013602 (2020).","journal-title":"Nature"},{"key":"800_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jnci\/djm288","volume":"100","author":"M Baba","year":"2008","unstructured":"Baba, M. et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J. Natl Cancer Inst. 100, 140\u2013154 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"800_CR63","doi-asserted-by":"publisher","first-page":"32761","DOI":"10.18632\/oncotarget.5018","volume":"6","author":"M Wu","year":"2015","unstructured":"Wu, M. et al. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. Oncotarget 6, 32761\u201332773 (2015).","journal-title":"Oncotarget"},{"key":"800_CR64","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/study\/NCT02504892 (2019)."},{"key":"800_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15866","volume":"8","author":"LA Laviolette","year":"2017","unstructured":"Laviolette, L. A. et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat. Commun. 8, 15866 (2017).","journal-title":"Nat. Commun."},{"key":"800_CR66","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/hmg\/ddy181","volume":"27","author":"H Hasumi","year":"2018","unstructured":"Hasumi, H. et al. BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Hum. Mol. Genet. 27, 2712\u20132724 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"800_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-59","volume":"3","author":"JA Klomp","year":"2010","unstructured":"Klomp, J. A. et al. Birt-Hogg-Dub\u00e9 renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med. Genomics 3, 59 (2010).","journal-title":"BMC Med. Genomics"},{"key":"800_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature10539","volume":"480","author":"C Bertolotto","year":"2011","unstructured":"Bertolotto, C. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480, 94\u201398 (2011).","journal-title":"Nature"},{"key":"800_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25618-z","volume":"12","author":"G Sun","year":"2021","unstructured":"Sun, G. et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat. Commun. 12, 5262 (2021).","journal-title":"Nat. Commun."},{"key":"800_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.path.2010.06.011","volume":"3","author":"EJ Perlman","year":"2010","unstructured":"Perlman, E. J. Pediatric renal cell carcinoma. Surgical Pathol. Clin. 3, 641\u2013651 (2010).","journal-title":"Surgical Pathol. Clin."},{"key":"800_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473\u2013477 (2009).","journal-title":"Science"},{"key":"800_CR72","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","volume":"332","author":"C Settembre","year":"2011","unstructured":"Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science 332, 1429\u20131433 (2011).","journal-title":"Science"},{"key":"800_CR73","doi-asserted-by":"publisher","first-page":"ra9","DOI":"10.1126\/scisignal.2004754","volume":"7","author":"JA Martina","year":"2014","unstructured":"Martina, J. A. et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal. 7, ra9 (2014).","journal-title":"Sci. Signal."},{"key":"800_CR74","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-18-0269","volume":"24","author":"NP Damayanti","year":"2018","unstructured":"Damayanti, N. P. et al. Therapeutic targeting of TFE3\/IRS-1\/PI3K\/mTOR axis in translocation renal cell carcinoma. Clin. Cancer Res. 24, 5977\u20135989 (2018).","journal-title":"Clin. Cancer Res."},{"key":"800_CR75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1086\/381054","volume":"74","author":"S Vanharanta","year":"2004","unstructured":"Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153\u2013159 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"800_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0002-9440(10)63091-X","volume":"164","author":"R Lehtonen","year":"2004","unstructured":"Lehtonen, R. et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am. J. Pathol. 164, 17\u201322 (2004).","journal-title":"Am. J. Pathol."},{"key":"800_CR77","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1074\/jbc.M608337200","volume":"282","author":"KS Hewitson","year":"2007","unstructured":"Hewitson, K. S. et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J. Biol. Chem. 282, 3293\u20133301 (2007).","journal-title":"J. Biol. Chem."},{"key":"800_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143\u2013153 (2005).","journal-title":"Cancer Cell"},{"key":"800_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77\u201385 (2005).","journal-title":"Cancer Cell"},{"key":"800_CR80","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao, M. et al. Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes. Dev. 26, 1326\u20131338 (2012).","journal-title":"Genes. Dev."},{"key":"800_CR81","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1093\/hmg\/ddm275","volume":"16","author":"EH Smith","year":"2007","unstructured":"Smith, E. H., Janknecht, R. & Maher, L. J. III Succinate inhibition of \u03b1-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet. 16, 3136\u20133148 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"800_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278108","volume":"17","author":"CJ Ricketts","year":"2022","unstructured":"Ricketts, C. J. et al. Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP). PLoS ONE\u00a017, e0278108 (2022).","journal-title":"PLoS ONE"},{"key":"800_CR83","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature19353","volume":"537","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli, M. et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537, 544\u2013547 (2016).","journal-title":"Nature"},{"key":"800_CR84","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","volume":"29","author":"JA Ligon","year":"2023","unstructured":"Ligon, J. A. et al. A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma. Clin. Cancer Res. 29, 341\u2013348 (2023).","journal-title":"Clin. Cancer Res."},{"key":"800_CR85","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","volume":"50","author":"PL Sulkowski","year":"2018","unstructured":"Sulkowski, P. L. et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat. Genet. 50, 1086\u20131092 (2018).","journal-title":"Nat. Genet."},{"key":"800_CR86","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.18632\/oncotarget.28273","volume":"13","author":"D Ueno","year":"2022","unstructured":"Ueno, D. et al. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget 13, 1054\u20131067 (2022).","journal-title":"Oncotarget"},{"key":"800_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2011.07.018","volume":"20","author":"WH Tong","year":"2011","unstructured":"Tong, W. H. et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20, 315\u2013327 (2011).","journal-title":"Cancer Cell"},{"key":"800_CR88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2011","unstructured":"Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385\u2013388 (2011).","journal-title":"Nature"},{"key":"800_CR89","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature10363","volume":"477","author":"C Frezza","year":"2011","unstructured":"Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225\u2013228 (2011).","journal-title":"Nature"},{"key":"800_CR90","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.euf.2021.12.002","volume":"8","author":"A Yoo","year":"2022","unstructured":"Yoo, A. et al. Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas. Eur. Urol. Focus. 8, 1278\u20131288 (2022).","journal-title":"Eur. Urol. Focus."},{"key":"800_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2049-3002-1-12","volume":"1","author":"L Zheng","year":"2013","unstructured":"Zheng, L. et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 1, 12 (2013).","journal-title":"Cancer Metab."},{"key":"800_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2006.03.005","volume":"450","author":"NL Alderson","year":"2006","unstructured":"Alderson, N. L. et al. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch. Biochem. Biophys. 450, 1\u20138 (2006).","journal-title":"Arch. Biochem. Biophys."},{"key":"800_CR93","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.celrep.2013.02.013","volume":"3","author":"N Ternette","year":"2013","unstructured":"Ternette, N. et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 3, 689\u2013700 (2013).","journal-title":"Cell Rep."},{"key":"800_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/path.2932","volume":"225","author":"C Bardella","year":"2011","unstructured":"Bardella, C. et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J. Pathol. 225, 4\u201311 (2011).","journal-title":"J. Pathol."},{"key":"800_CR95","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","volume":"20","author":"J Adam","year":"2011","unstructured":"Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524\u2013537 (2011).","journal-title":"Cancer Cell"},{"key":"800_CR96","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41589-018-0217-y","volume":"15","author":"RA Kulkarni","year":"2019","unstructured":"Kulkarni, R. A. et al. A chemoproteomic portrait of the oncometabolite fumarate. Nat. Chem. Biol. 15, 391\u2013400 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"800_CR97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton, C. J. et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"800_CR98","doi-asserted-by":"publisher","first-page":"871252","DOI":"10.3389\/fonc.2022.871252","volume":"12","author":"DD Shapiro","year":"2022","unstructured":"Shapiro, D. D., Virumbrales-Mu\u00f1oz, M., Beebe, D. J. & Abel, E. J. Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics. Front. Oncol. 12, 871252 (2022).","journal-title":"Front. Oncol."},{"key":"800_CR99","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/his.14700","volume":"81","author":"J Lobo","year":"2022","unstructured":"Lobo, J. et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology 81, 426\u2013438 (2022).","journal-title":"Histopathology"},{"key":"800_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78174-9","volume":"10","author":"H Pan","year":"2020","unstructured":"Pan, H., Ye, L., Zhu, Q., Yang, Z. & Hu, M. The effect of the papillary renal cell carcinoma subtype on oncological outcomes. Sci. Rep. 10, 21073 (2020).","journal-title":"Sci. Rep."},{"key":"800_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27660-3","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma. Nat. Commun. 13, 31 (2022).","journal-title":"Nat. Commun."},{"key":"800_CR102","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","volume":"20","author":"L Albiges","year":"2014","unstructured":"Albiges, L. et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin. Cancer Res. 20, 3411\u20133421 (2014).","journal-title":"Clin. Cancer Res."},{"key":"800_CR103","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-14-2685","volume":"21","author":"AG Schuller","year":"2015","unstructured":"Schuller, A. G. et al. The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient\u2013derived xenograft models. Clin. Cancer Res. 21, 2811\u20132819 (2015).","journal-title":"Clin. Cancer Res."},{"key":"800_CR104","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/cancers15030565","volume":"15","author":"NS Chawla","year":"2023","unstructured":"Chawla, N. S. et al. An update on the treatment of papillary renal cell carcinoma. Cancers 15, 565 (2023).","journal-title":"Cancers"},{"key":"800_CR105","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","volume":"397","author":"SK Pal","year":"2021","unstructured":"Pal, S. K. et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397, 695\u2013703 (2021).","journal-title":"Lancet"},{"key":"800_CR106","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch, H. et al. The 2022 World Health organization classification of tumours of the urinary system and male genital organs \u2014 part A: renal, penile, and testicular tumours. Eur. Urol. 82, 458\u2013468 (2022).","journal-title":"Eur. Urol."},{"key":"800_CR107","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/cancers11091298","volume":"11","author":"AA Ahmad","year":"2019","unstructured":"Ahmad, A. A. et al. Papillary renal cell carcinomas rewire glutathione metabolism and are deficient in both anabolic glucose synthesis and oxidative phosphorylation. Cancers 11, 1298 (2019).","journal-title":"Cancers"},{"key":"800_CR108","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/jcp.30130","volume":"236","author":"C Sun","year":"2021","unstructured":"Sun, C. et al. Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma. J. Cell. Physiol. 236, 3821\u20133831 (2021).","journal-title":"J. Cell. Physiol."},{"key":"800_CR109","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1007\/s00330-017-4875-z","volume":"27","author":"R Nakajima","year":"2017","unstructured":"Nakajima, R. et al. Evaluation of renal cell carcinoma histological subtype and Fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography\/computed tomography. Eur. Radiol. 27, 4866\u20134873 (2017).","journal-title":"Eur. Radiol."},{"key":"800_CR110","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326.e5 (2018).","journal-title":"Cell Rep."},{"key":"800_CR111","doi-asserted-by":"publisher","first-page":"eabp8293","DOI":"10.1126\/sciadv.abp8293","volume":"8","author":"AK Kaushik","year":"2022","unstructured":"Kaushik, A. K. et al. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci. Adv. 8, eabp8293 (2022).","journal-title":"Sci. Adv."},{"key":"800_CR112","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1464-410X.2011.10690.x","volume":"110","author":"A Volpe","year":"2012","unstructured":"Volpe, A. et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 110, 76\u201383 (2012).","journal-title":"BJU Int."},{"key":"800_CR113","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","volume":"26","author":"CF Davis","year":"2014","unstructured":"Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319\u2013330 (2014).","journal-title":"Cancer Cell"},{"key":"800_CR114","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/ng.3146","volume":"47","author":"S Durinck","year":"2015","unstructured":"Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13\u201321 (2015).","journal-title":"Nat. Genet."},{"key":"800_CR115","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/s41379-020-0607-z","volume":"33","author":"JM Roldan-Romero","year":"2020","unstructured":"Roldan-Romero, J. M. et al. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Mod. Pathol. 33, 2580\u20132590 (2020).","journal-title":"Mod. Pathol."},{"key":"800_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92688","volume":"2","author":"J Casuscelli","year":"2017","unstructured":"Casuscelli, J. et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2, e92688 (2017).","journal-title":"JCI Insight"},{"key":"800_CR117","doi-asserted-by":"publisher","first-page":"103287","DOI":"10.1016\/j.critrevonc.2021.103287","volume":"160","author":"R Garje","year":"2021","unstructured":"Garje, R. et al. Comprehensive review of chromophobe renal cell carcinoma. Crit. Rev. Oncol. Hematol. 160, 103287 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"800_CR118","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/00000478-200009000-00008","volume":"24","author":"SK Tickoo","year":"2000","unstructured":"Tickoo, S. K. et al. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am. J. Surg. Pathol. 24, 1247\u20131256 (2000).","journal-title":"Am. J. Surg. Pathol."},{"key":"800_CR119","doi-asserted-by":"publisher","unstructured":"Divya, B. et al. Mitochondrial metabolism in primary and metastatic human kidney cancers. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2023.02.06.527285 (2023).","DOI":"10.1101\/2023.02.06.527285"},{"key":"800_CR120","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.euf.2018.01.016","volume":"5","author":"E Schaeffeler","year":"2019","unstructured":"Schaeffeler, E. et al. Metabolic and lipidomic reprogramming in renal cell carcinoma subtypes reflects regions of tumor origin. Eur. Urol. Focus. 5, 608\u2013618 (2019).","journal-title":"Eur. Urol. Focus."},{"key":"800_CR121","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-20-1998","volume":"80","author":"Y Xiao","year":"2020","unstructured":"Xiao, Y. et al. Endocytosis-mediated replenishment of amino acids favors cancer cell proliferation and survival in chromophobe renal cell carcinoma. Cancer Res. 80, 5491\u20135501 (2020).","journal-title":"Cancer Res."},{"key":"800_CR122","doi-asserted-by":"publisher","first-page":"E6274","DOI":"10.1073\/pnas.1710849115","volume":"115","author":"C Priolo","year":"2018","unstructured":"Priolo, C. et al. Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proc. Natl Acad. Sci. USA 115, E6274\u2013E6282 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122840119","volume":"119","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proc. Natl Acad. Sci. USA 119, e2122840119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR124","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00432-020-03278-8","volume":"146","author":"AG Simon","year":"2020","unstructured":"Simon, A. G. et al. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. J. Cancer Res. Clin. Oncol. 146, 2255\u20132265 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"800_CR125","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semnephrol.2018.01.006","volume":"38","author":"RH Weiss","year":"2018","unstructured":"Weiss, R. H. Metabolomics and metabolic reprogramming in kidney cancer. Semin. Nephrol. 38, 175\u2013182 (2018).","journal-title":"Semin. Nephrol."},{"key":"800_CR126","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277\u2013285 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"800_CR127","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2012.06.002","volume":"23","author":"WM Linehan","year":"2013","unstructured":"Linehan, W. M. & Ricketts, C. J. The metabolic basis of kidney cancer. Semin. Cancer Biol. 23, 46\u201355 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"800_CR128","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104\u2013116 (2016).","journal-title":"Cancer Cell"},{"key":"800_CR129","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964\u2013983.e931 (2019).","journal-title":"Cell"},{"key":"800_CR130","doi-asserted-by":"publisher","first-page":"13371","DOI":"10.18632\/oncotarget.3823","volume":"6","author":"G Lucarelli","year":"2015","unstructured":"Lucarelli, G. et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget 6, 13371\u201313386 (2015).","journal-title":"Oncotarget"},{"key":"800_CR131","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","volume":"75","author":"HI Wettersten","year":"2015","unstructured":"Wettersten, H. I. et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541\u20132552 (2015).","journal-title":"Cancer Res."},{"key":"800_CR132","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cmet.2018.07.020","volume":"28","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab. 28, 793\u2013800.e792 (2018).","journal-title":"Cell Metab."},{"key":"800_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193477","volume":"13","author":"D Ambrosetti","year":"2018","unstructured":"Ambrosetti, D. et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS ONE\u00a013, e0193477 (2018).","journal-title":"PLoS ONE"},{"key":"800_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-101","volume":"13","author":"H Girgis","year":"2014","unstructured":"Girgis, H. et al. Lactate dehydrogenase a is a potential prognostic marker in clear cell renal cell carcinoma. Mol. Cancer 13, 101 (2014).","journal-title":"Mol. Cancer"},{"key":"800_CR135","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.humpath.2014.09.013","volume":"46","author":"Y Kim","year":"2015","unstructured":"Kim, Y., Choi, J.-W., Lee, J.-H. & Kim, Y.-S. Expression of lactate\/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum. Pathol. 46, 104\u2013112 (2015).","journal-title":"Hum. Pathol."},{"key":"800_CR136","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/ijc.25543","volume":"128","author":"K Singer","year":"2011","unstructured":"Singer, K. et al. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8+ T-cell infiltration in the tumor. Int. J. Cancer 128, 2085\u20132095 (2011).","journal-title":"Int. J. Cancer"},{"key":"800_CR137","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.7150\/ijbs.58295","volume":"17","author":"W Xu","year":"2021","unstructured":"Xu, W. et al. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte\/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. Int. J. Biol. Sci. 17, 2205\u20132222 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"800_CR138","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282\u2013288 (2021).","journal-title":"Nature"},{"key":"800_CR139","doi-asserted-by":"publisher","first-page":"108500","DOI":"10.1016\/j.celrep.2020.108500","volume":"33","author":"WJ Quinn III","year":"2020","unstructured":"Quinn, W. J. III et al. Lactate limits T cell proliferation via the NAD(H) Redox State. Cell Rep. 33, 108500 (2020).","journal-title":"Cell Rep."},{"key":"800_CR140","doi-asserted-by":"publisher","first-page":"113502","DOI":"10.18632\/oncotarget.23056","volume":"8","author":"C Bianchi","year":"2017","unstructured":"Bianchi, C. et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget 8, 113502\u2013113515 (2017).","journal-title":"Oncotarget"},{"key":"800_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.545","volume":"6","author":"H Nilsson","year":"2015","unstructured":"Nilsson, H. et al. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-bromopyruvate. Cell Death Dis. 6, e1585 (2015).","journal-title":"Cell Death Dis."},{"key":"800_CR142","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1158\/1940-6207.CAPR-11-0338","volume":"5","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev. Res. 5, 717\u2013725 (2012).","journal-title":"Cancer Prev. Res."},{"key":"800_CR143","doi-asserted-by":"crossref","unstructured":"Wang, J. et al. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma. Oncotarget 7 (2016).","DOI":"10.18632\/oncotarget.8382"},{"key":"800_CR144","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/path.4006","volume":"227","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J. Pathol. 227, 146\u2013156 (2012).","journal-title":"J. Pathol."},{"key":"800_CR145","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1021\/acs.jmedchem.2c01342","volume":"66","author":"FW Goldberg","year":"2023","unstructured":"Goldberg, F. W. et al. Discovery of clinical candidate AZD0095, a selective inhibitor of monocarboxylate transporter 4 (MCT4) for oncology. J. Med. Chem. 66, 384\u2013397 (2023).","journal-title":"J. Med. Chem."},{"key":"800_CR146","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford, S. et al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin. Cancer Res. 29, 1429\u20131439 (2023).","journal-title":"Clin. Cancer Res."},{"key":"800_CR147","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.1111\/jcmm.15536","volume":"24","author":"W-H Xu","year":"2020","unstructured":"Xu, W.-H. et al. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. J. Cell. Mol. Med. 24, 9012\u20139027 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"800_CR148","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature13557","volume":"513","author":"B Li","year":"2014","unstructured":"Li, B. et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513, 251\u2013255 (2014).","journal-title":"Nature"},{"key":"800_CR149","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2147\/OTT.S241717","volume":"13","author":"L Shi","year":"2020","unstructured":"Shi, L., An, S., Liu, Y., Liu, J. & Wang, F. PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA. Onco Targets Ther. 13, 2613\u20132627 (2020).","journal-title":"Onco Targets Ther."},{"key":"800_CR150","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40170-022-00280-1","volume":"10","author":"J Godfrey","year":"2022","unstructured":"Godfrey, J., Riscal, R., Skuli, N. & Simon, M. C. Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cells. Cancer Metab. 10, 4 (2022).","journal-title":"Cancer Metab."},{"key":"800_CR151","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s42255-021-00367-x","volume":"3","author":"H Xie","year":"2021","unstructured":"Xie, H. et al. Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma. Nat. Metab. 3, 327\u2013336 (2021).","journal-title":"Nat. Metab."},{"key":"800_CR152","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clon.2011.03.005","volume":"24","author":"MR Safarinejad","year":"2012","unstructured":"Safarinejad, M. R., Shafiei, N. & Safarinejad, S. Methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C and G1793A polymorphisms: association with risk for clear cell renal cell carcinoma and tumour behaviour in men. Clin. Oncol. 24, 269\u2013281 (2012).","journal-title":"Clin. Oncol."},{"key":"800_CR153","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-17-1589","volume":"77","author":"H Yoshino","year":"2017","unstructured":"Yoshino, H. et al. PHGDH as a key enzyme for serine biosynthesis in HIF2\u03b1-targeting therapy for renal cell carcinoma. Cancer Res. 77, 6321\u20136329 (2017).","journal-title":"Cancer Res."},{"key":"800_CR154","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106947118","volume":"118","author":"RK Aggarwal","year":"2021","unstructured":"Aggarwal, R. K. et al. Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer. Proc. Natl Acad. Sci. USA 118, e2106947118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR155","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.freeradbiomed.2019.01.030","volume":"134","author":"Y Ma","year":"2019","unstructured":"Ma, Y. et al. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis. Free Radic. Biol. Med. 134, 458\u2013467 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"800_CR156","doi-asserted-by":"publisher","first-page":"639408","DOI":"10.3389\/fonc.2021.639408","volume":"11","author":"Z Fang","year":"2021","unstructured":"Fang, Z., Sun, Q., Yang, H. & Zheng, J. SDHB suppresses the tumorigenesis and development of ccRCC by inhibiting glycolysis. Front. Oncol. 11, 639408 (2021).","journal-title":"Front. Oncol."},{"key":"800_CR157","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/10799893.2021.1883060","volume":"42","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. Upregulation of SDHA inhibited proliferation, migration, and invasion of clear cell renal cell carcinoma cells via inactivation of the Wnt\/\u03b2-catenin pathway. J. Recept. Signal. Transduct. Res. 42, 180\u2013188 (2022).","journal-title":"J. Recept. Signal. Transduct. Res."},{"key":"800_CR158","doi-asserted-by":"publisher","first-page":"86490","DOI":"10.18632\/oncotarget.13275","volume":"7","author":"J Ellinger","year":"2016","unstructured":"Ellinger, J. et al. Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget 7, 86490\u201386499 (2016).","journal-title":"Oncotarget"},{"key":"800_CR159","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/j.clgc.2016.11.010","volume":"15","author":"J Ellinger","year":"2017","unstructured":"Ellinger, J. et al. Systematic expression analysis of mitochondrial complex I identifies NDUFS1 as a biomarker in clear-cell renal-cell carcinoma. Clin. Genitourin. Cancer 15, e551\u2013e562 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"800_CR160","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.tranon.2017.06.002","volume":"10","author":"M Br\u00fcggemann","year":"2017","unstructured":"Br\u00fcggemann, M. et al. systematic analysis of the expression of the mitochondrial ATP synthase (Complex V) subunits in clear cell renal cell carcinoma. Transl. Oncol. 10, 661\u2013668 (2017).","journal-title":"Transl. Oncol."},{"key":"800_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72107-2","volume":"10","author":"Y Luo","year":"2020","unstructured":"Luo, Y. et al. UQCRH downregulation promotes Warburg effect in renal cell carcinoma cells. Sci. Rep. 10, 15021 (2020).","journal-title":"Sci. Rep."},{"key":"800_CR162","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/1878-0261.13040","volume":"16","author":"K Miyakuni","year":"2022","unstructured":"Miyakuni, K. et al. Genome-wide analysis of DNA methylation identifies the apoptosis-related gene UQCRH as a tumor suppressor in renal cancer. Mol. Oncol. 16, 732\u2013749 (2022).","journal-title":"Mol. Oncol."},{"key":"800_CR163","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.cmet.2011.10.008","volume":"14","author":"D Tello","year":"2011","unstructured":"Tello, D. et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1\u03b1 decreases oxygen consumption by inhibiting complex I activity. Cell Metab. 14, 768\u2013779 (2011).","journal-title":"Cell Metab."},{"key":"800_CR164","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/0886022X.2016.1208517","volume":"38","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. NDUFA4L2 expression predicts poor prognosis in clear cell renal cell carcinoma patients. Ren. Fail. 38, 1199\u20131205 (2016).","journal-title":"Ren. Fail."},{"key":"800_CR165","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.18632\/aging.101685","volume":"10","author":"G Lucarelli","year":"2018","unstructured":"Lucarelli, G. et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging 10, 3957\u20133985 (2018).","journal-title":"Aging"},{"key":"800_CR166","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-15-1511","volume":"22","author":"DR Minton","year":"2016","unstructured":"Minton, D. R. et al. Role of NADH dehydrogenase (Ubiquinone) 1 alpha subcomplex 4-like 2 in clear cell renal cell carcinoma. Clin. Cancer Res. 22, 2791\u20132801 (2016).","journal-title":"Clin. Cancer Res."},{"key":"800_CR167","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.eururo.2015.09.014","volume":"69","author":"A Kinnaird","year":"2016","unstructured":"Kinnaird, A. et al. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur. Urol. 69, 734\u2013744 (2016).","journal-title":"Eur. Urol."},{"key":"800_CR168","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cmet.2018.04.009","volume":"27","author":"JD Ochocki","year":"2018","unstructured":"Ochocki, J. D. et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity. Cell Metab. 27, 1263\u20131280.e6 (2018).","journal-title":"Cell Metab."},{"key":"800_CR169","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40170-021-00271-8","volume":"9","author":"S Khare","year":"2021","unstructured":"Khare, S. et al. ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism. Cancer Metab. 9, 40 (2021).","journal-title":"Cancer Metab."},{"key":"800_CR170","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ijc.22322","volume":"120","author":"CY Yoon","year":"2007","unstructured":"Yoon, C. Y. et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int. J. Cancer 120, 897\u2013905 (2007).","journal-title":"Int. J. Cancer"},{"key":"800_CR171","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1158\/0008-5472.CAN-17-0930","volume":"77","author":"O Abu Aboud","year":"2017","unstructured":"Abu Aboud, O. et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res. 77, 6746\u20136758 (2017).","journal-title":"Cancer Res."},{"key":"800_CR172","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","volume":"17","author":"PA Gameiro","year":"2013","unstructured":"Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17, 372\u2013385 (2013).","journal-title":"Cell Metab."},{"key":"800_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15965","volume":"8","author":"DE Biancur","year":"2017","unstructured":"Biancur, D. E. et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat. Commun. 8, 15965 (2017).","journal-title":"Nat. Commun."},{"key":"800_CR174","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin. Cancer Res. 28, 1540\u20131548 (2022).","journal-title":"Clin. Cancer Res."},{"key":"800_CR175","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","volume":"28","author":"C-H Lee","year":"2022","unstructured":"Lee, C.-H. et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial. Clin. Cancer Res. 28, 3248\u20133255 (2022).","journal-title":"Clin. Cancer Res."},{"key":"800_CR176","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","volume":"8","author":"NM Tannir","year":"2022","unstructured":"Tannir, N. M. et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial. JAMA Oncol. 8, 1411\u20131418, (2022).","journal-title":"JAMA Oncol."},{"key":"800_CR177","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1073\/pnas.1116573109","volume":"109","author":"K Thangavelu","year":"2012","unstructured":"Thangavelu, K. et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc. Natl Acad. Sci. USA 109, 7705\u20137710 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR178","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000421-198210000-00014","volume":"5","author":"G Lynch","year":"1982","unstructured":"Lynch, G., Kemeny, N. & Casper, E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am. J. Clin. Oncol. 5, 541\u2013543 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"800_CR179","doi-asserted-by":"publisher","first-page":"eabq5925","DOI":"10.1126\/sciadv.abq5925","volume":"8","author":"R Rais","year":"2022","unstructured":"Rais, R. et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci. Adv. 8, eabq5925 (2022).","journal-title":"Sci. Adv."},{"key":"800_CR180","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/study\/NCT04471415 (2023)."},{"key":"800_CR181","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1541-7786.MCR-18-1204","volume":"17","author":"A Bansal","year":"2019","unstructured":"Bansal, A. et al. Gamma-glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression. Mol. Cancer Res. 17, 1881\u20131892 (2019).","journal-title":"Mol. Cancer Res."},{"key":"800_CR182","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1038\/s41388-018-0315-z","volume":"37","author":"H Miess","year":"2018","unstructured":"Miess, H. et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene 37, 5435\u20135450 (2018).","journal-title":"Oncogene"},{"key":"800_CR183","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-15-2328","volume":"76","author":"X Tang","year":"2016","unstructured":"Tang, X. et al. Cystine deprivation triggers programmed necrosis in VHL-deficient renal cell carcinomas. Cancer Res. 76, 1892\u20131903 (2016).","journal-title":"Cancer Res."},{"key":"800_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09277-9","volume":"10","author":"Y Zou","year":"2019","unstructured":"Zou, Y. et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 10, 1617 (2019).","journal-title":"Nat. Commun."},{"key":"800_CR185","doi-asserted-by":"publisher","first-page":"a004838","DOI":"10.1101\/cshperspect.a004838","volume":"3","author":"T Fujimoto","year":"2011","unstructured":"Fujimoto, T. & Parton, R. G. Not just fat: the structure and function of the lipid droplet. Cold Spring Harb. Perspect. Biol. 3, a004838 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"800_CR186","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","volume":"20","author":"SK Tan","year":"2023","unstructured":"Tan, S. K., Hougen, H. Y., Merchan, J. R., Gonzalgo, M. L. & Welford, S. M. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nat. Rev. Urol. 20, 48\u201360 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"800_CR187","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu, B. et al. HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 5, 652\u2013667 (2015).","journal-title":"Cancer Discov."},{"key":"800_CR188","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0022-2275(20)38606-5","volume":"28","author":"RL Gebhard","year":"1987","unstructured":"Gebhard, R. L. et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J. Lipid Res. 28, 1177\u20131184 (1987).","journal-title":"J. Lipid Res."},{"key":"800_CR189","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3761-z","volume":"18","author":"G-H Xu","year":"2018","unstructured":"Xu, G.-H. et al. Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. BMC Cancer 18, 88 (2018).","journal-title":"BMC Cancer"},{"key":"800_CR190","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/lt.24349","volume":"22","author":"IA Rowe","year":"2016","unstructured":"Rowe, I. A. et al. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl. 22, 287\u2013297 (2016).","journal-title":"Liver Transpl."},{"key":"800_CR191","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191\u20131193 (1998).","journal-title":"Science"},{"key":"800_CR192","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten, M., Nollen, E. A. A., R\u00f6hrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug. Discov. 18, 379\u2013401 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"800_CR193","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.20020121","volume":"196","author":"G Frumento","year":"2002","unstructured":"Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459\u2013468 (2002).","journal-title":"J. Exp. Med."},{"key":"800_CR194","doi-asserted-by":"publisher","first-page":"461.e415","DOI":"10.1016\/j.urolonc.2017.02.011","volume":"35","author":"G Lucarelli","year":"2017","unstructured":"Lucarelli, G. et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol. Oncol. 35, 461.e415\u2013461.e427 (2017).","journal-title":"Urol. Oncol."},{"key":"800_CR195","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-07-0942","volume":"13","author":"R Riesenberg","year":"2007","unstructured":"Riesenberg, R. et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 13, 6993\u20137002 (2007).","journal-title":"Clin. Cancer Res."},{"key":"800_CR196","doi-asserted-by":"publisher","first-page":"66540","DOI":"10.18632\/oncotarget.11658","volume":"7","author":"JF Trott","year":"2016","unstructured":"Trott, J. F. et al. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget 7, 66540\u201366557 (2016).","journal-title":"Oncotarget"},{"key":"800_CR197","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","volume":"11","author":"LM Minasian","year":"1993","unstructured":"Minasian, L. M. et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11, 1368\u20131375 (1993).","journal-title":"J. Clin. Oncol."},{"key":"800_CR198","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2018.36.15_suppl.108","volume":"36","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301\/KEYNOTE-252 study. J. Clin. Oncol. 36, 108\u2013108 (2018).","journal-title":"J. Clin. Oncol."},{"key":"800_CR199","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29, 115\u2013126 (2023).","journal-title":"Nat. Med."},{"key":"800_CR200","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1158\/0008-5472.CAN-16-0266","volume":"76","author":"C Lehu\u00e9d\u00e9","year":"2016","unstructured":"Lehu\u00e9d\u00e9, C., Dupuy, F., Rabinovitch, R., Jones, R. G. & Siegel, P. M. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 76, 5201\u20135208 (2016).","journal-title":"Cancer Res."},{"key":"800_CR201","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"800_CR202","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"800_CR203","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009 (2017).","journal-title":"Nat. Rev. Dis. Prim."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00800-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00800-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00800-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T10:13:08Z","timestamp":1710929588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00800-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":203,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1038\/s41581-023-00800-2","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"30 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}